| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285
A human adenocarcinoma-associated antigen (KSA) defined by the monoclonal antibody KS1/4 has become the focus of several site-directed strategies for tumor therapy. KSA, a 40,000 Da cell surface glycoprotein antigen, is found at a high density in all adenocarcinomas examined to date and in corresponding normal epithelial tissues. Here we describe the cloning and sequencing of overlapping complementary DNA clones which encode the entire KSA as expressed in UCLA-P3, a human lung adenocarcinoma cell line. We have deduced the 314-amino acid sequence and have compared it to the N-terminal amino acid sequence data of the affinity-purified antigen. The KSA is synthesized as a 314-residue-long preproprotein that is then processed to a 232-residue-long antigen. KSA appears to have a single transmembrane domain of 23 residues that separates the highly charged 26-residue cytoplasmic domain from the extracellular domain. The N-terminal region of the propeptide is rich in cysteines and contains three potential N-glycosylation sites. Computer-assisted analyses at both the DNA and protein levels have found no significant similarities of this protein to known sequences, but a GC-rich 5' terminus is evident. Northern blot analysis shows that transcription of KSA can be detected in RNA isolated from normal colon but not in RNA isolated from normal lung, prostate, or liver.
1 To whom requests for reprints should be addressed.
Received 8/25/88. Revised 10/11/88. Accepted 10/17/88.
This article has been cited by other articles:
|
|
 |
|
  M. Trzpis, P. M.J. McLaughlin, L. M.F.H. de Leij, and M. C. Harmsen Epithelial Cell Adhesion Molecule: More than a Carcinoma Marker and Adhesion Molecule Am. J. Pathol., August 1, 2007; 171(2): 386 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Schmelzer, E. Wauthier, and L. M. Reid The Phenotypes of Pluripotent Human Hepatic Progenitors Stem Cells, August 1, 2006; 24(8): 1852 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. de Bono, A. W. Tolcher, A. Forero, G. F. A. Vanhove, C. Takimoto, R. J. Bauer, L. A. Hammond, A. Patnaik, M. L. White, S. Shen, et al. ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas Clin. Cancer Res., November 15, 2004; 10(22): 7555 - 7565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Winter, I. D. Nagtegaal, J. H. J. M. van Krieken, and S. V. Litvinov The Epithelial Cell Adhesion Molecule (Ep-CAM) as a Morphoregulatory Molecule Is a Tool in Surgical Pathology Am. J. Pathol., December 1, 2003; 163(6): 2139 - 2148. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Mitas, L. Hoover, G. Silvestri, C. Reed, M. Green, A. T. Turrisi, C. Sherman, K. Mikhitarian, D. J. Cole, M. I. Block, et al. Lunx Is a Superior Molecular Marker for Detection of Non-Small Lung Cell Cancer in Peripheral Blood J. Mol. Diagn., November 1, 2003; 5(4): 237 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Kim, D. Herlyn, K.-k. Wong, D.-C. Park, J. O. Schorge, K. H. Lu, S. J. Skates, D. W. Cramer, R. S. Berkowitz, and S. C. Mok Identification of Epithelial Cell Adhesion Molecule Autoantibody in Patients with Ovarian Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4782 - 4791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Stephan, S. Schanz, A. Wong, P. Schow, and W. L. T. Wong Development of a Frozen Cell Array as a High-Throughput Approach for Cell-Based Analysis Am. J. Pathol., September 1, 2002; 161(3): 787 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Stephan, P. E. Roberts, L. Bald, J. Lee, Q. Gu, B. Devaux, and J. P. Mather Selective Cloning of Cell Surface Proteins Involved in Organ Development: Epithelial Glycoprotein Is Involved in Normal Epithelial Differentiation Endocrinology, December 1, 1999; 140(12): 5841 - 5854. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Graves, S. C. Goshorn, D. M. Stone, D. B. Axworthy, J. M. Reno, B. Bottino, S. Searle, A. Henry, J. Pedersen, A. R. Rees, et al. Molecular Modeling and Preclinical Evaluation of the Humanized NR-LU-13 Antibody Clin. Cancer Res., April 1, 1999; 5(4): 899 - 908. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
